{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:42:09Z","timestamp":1778848929597,"version":"3.51.4"},"reference-count":39,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:00:00Z","timestamp":1709424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Primary cutaneous B-cell lymphomas (PCBCLs) are B-cell lymphomas that can occur in the skin without evidence of extracutaneous involvement. The 2005 WHO\/EORTC classification of cutaneous lymphomas and its 2018 update have distinguished three main categories based on clinicopathological, immunohistochemical, and genetic characteristics: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle centre lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT). PCMZL and PCFCL are clinically indolent, while PCDLBCL-LT is an aggressive lymphoma. Due to its low incidence and lack of prospective studies, it is difficult to establish a standard treatment for each subgroup. The objective of our study was to describe the clinical and pathological characteristics of 103 patients with cutaneous B-cell lymphoma from 12 centres belonging to the Spanish Lymphoma Oncology Group. The median age was 53 years (40\u201365). According to skin extension, 62% had single-site lymphoma, 17% had regional lymphoma, and 20% had multifocal lymphoma. Histology: 66% had PCMZL, 26% had PCFCL, and 8% had PCDLBCL-LT. Twenty-three percent of the patients were treated exclusively with surgery, 26% with radiotherapy only, 21% with surgery plus radiotherapy, 10% with polychemotherapy, and 5% with rituximab monotherapy. Overall, 96% of patients achieved a complete response, and 44% subsequently relapsed, most of them relapsing either locally or regionally. The 10-year OS was 94.5% for the entire cohort, 98% for the PCMZL cohort, 95% for the PCFCL cohort, and 85.7% for the PCDLBCL-LT cohort. Our data are comparable to those of other published series, except for the high frequency of PCMZL. The expected heterogeneity in therapeutic management has been observed.<\/jats:p>","DOI":"10.3390\/cancers16051034","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T04:36:21Z","timestamp":1709526981000},"page":"1034","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL)"],"prefix":"10.3390","volume":"16","author":[{"given":"Natividad","family":"Mart\u00ednez-Banaclocha","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Hospital General Universitario Dr. Balmis, Institute for Health and Biomedical Research (ISABIAL), 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Mart\u00ednez-Madue\u00f1o","sequence":"additional","affiliation":[{"name":"Southern Catalonia Institute of Oncology, Hospital Universitari Sant Joan de Reus, IISPV-URV-CERCA, 43204 Reus, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berta","family":"Caball\u00e9","sequence":"additional","affiliation":[{"name":"Southern Catalonia Institute of Oncology, Hospital Universitari Sant Joan de Reus, IISPV-URV-CERCA, 43204 Reus, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7446-7365","authenticated-orcid":false,"given":"Joan","family":"Badia","sequence":"additional","affiliation":[{"name":"Southern Catalonia Institute of Oncology, Hospital Universitari Sant Joan de Reus, IISPV-URV-CERCA, 43204 Reus, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Blanes","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital General Universitario Dr. Balmis, Institute for Health and Biomedical Research (ISABIAL), 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Aguiar","family":"Bujanda","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrin, 35010 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Calvo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"G\u00f3mez Codina","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7249-0138","authenticated-orcid":false,"given":"Cristina Quero","family":"Blanco","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Infanta Cristina, 28981 Parla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Lavernia","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda (I.V.O.), 46009 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Ram\u00f3n Garc\u00eda","family":"Arroyo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Complexo Hospitalario Universitario de Pontevedra, 36071 Pontevedra, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Guirado","family":"Risue\u00f1o","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital General Universitario de Elche, 03203 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Llorca","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital General Universitario de Elda, 03600 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-4247","authenticated-orcid":false,"given":"Raquel","family":"Cumeras","sequence":"additional","affiliation":[{"name":"Southern Catalonia Institute of Oncology, Hospital Universitari Sant Joan de Reus, IISPV-URV-CERCA, 43204 Reus, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6315-7919","authenticated-orcid":false,"given":"Mariano Provencio","family":"Pulla","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Gum\u00e0","sequence":"additional","affiliation":[{"name":"Southern Catalonia Institute of Oncology, Hospital Universitari Sant Joan de Reus, IISPV-URV-CERCA, 43204 Reus, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","article-title":"Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: Comparison with previous classifications and identification of prognostic markers","volume":"25","author":"Senff","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_3","first-page":"1112","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"134","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"ref_4","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.det.2022.07.014","article-title":"A Practical Review of the Presentation, Diagnosis, and Management of Cutaneous B-Cell Lymphomas","volume":"41","author":"Goyal","year":"2023","journal-title":"Dermatol. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","article-title":"TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1309\/AJCP4SUBR4NPSPTN","article-title":"Diagnostic and prognostic value of BCL2 rearrangement in 53 patients with follicular lymphoma presenting as primary skin lesions","volume":"143","author":"Doussau","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_10","unstructured":"Guinard, E., Alenezi, F., Lamant, L., Szablewski, V., Tournier, E., Laurent, C., Paul, C., Meyer, N., Dereure, O., and Boulinguez, S. (2019). Staging of primary cutaneous follicle centre B-cell lymphoma: Bone marrow biopsy, CD10, BCL2 and t(14;18) are not relevant prognostic factors. Eur. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/bjd.14932","article-title":"Paediatric primary cutaneous marginal zone B-cell lymphoma: Does it differ from its adult counterpart?","volume":"176","author":"Tavallaee","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Dumont, M., Battistella, M., Ram-Wolff, C., Bagot, M., and de Masson, A. (2020). Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives. Cancers, 12.","DOI":"10.3390\/cancers12061497"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.semdp.2016.11.007","article-title":"Cutaneous marginal zone lymphomas","volume":"34","author":"Swerdlow","year":"2017","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1600-0560.1997.tb01318.x","article-title":"Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma","volume":"24","author":"Cerroni","year":"1997","journal-title":"J. Cutan. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1468-3083.2006.01485.x","article-title":"Primary cutaneous MALT-type lymphoma and Helicobacter pylori: A possible relationship","volume":"20","author":"Delli","year":"2006","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2005.04.036","article-title":"Cutaneous lymphoid hyperplasia and marginal zone B-cell lymphoma following vaccination","volume":"53","author":"May","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jamadermatol.2013.9223","article-title":"High incidence of gastrointestinal tract disorders and autoimmunity in primary cutaneous marginal zone B-cell lymphomas","volume":"150","author":"Guitart","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/PAS.0b013e3181f72835","article-title":"Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets","volume":"34","author":"Edinger","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archderm.1996.03890350042008","article-title":"Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group","volume":"132","author":"Vermeer","year":"1996","journal-title":"Arch. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/modpathol.2013.156","article-title":"Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma","volume":"27","author":"Andrique","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/PAS.0000000000000851","article-title":"Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets","volume":"41","author":"Mitteldorf","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3109\/10428194.2012.723707","article-title":"Radiotherapy in the management of localized primary cutaneous B-cell lymphoma","volume":"54","author":"Pashtan","year":"2013","journal-title":"Leuk. Lymphoma."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: Field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas","volume":"74","author":"Neelis","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_26","first-page":"694","article-title":"Treatment of cutaneous lymphomas: An update","volume":"103","year":"2012","journal-title":"Actas Dermosifiliogr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2340\/00015555-1113","article-title":"Systemic rituximab in multifocal primary cutaneous follicle centre lymphoma","volume":"91","author":"Brocard","year":"2011","journal-title":"Acta Derm. Venereol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2133.2012.10902.x","article-title":"Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: An epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma","volume":"167","author":"Santiago","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/j.clml.2021.10.009","article-title":"Characterization of Primary and Secondary Cutaneous B-Cell Lymphomas: A Population-Based Study of 4758 Patients","volume":"22","author":"Leary","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_30","first-page":"1379","article-title":"Borrelia burgdorferi in primary cutaneous lymphomas: A systematic review and meta-analysis","volume":"18","author":"Travaglino","year":"2020","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ad.2022.11.013","article-title":"Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years","volume":"114","author":"Muniesa","year":"2023","journal-title":"Actas Dermosifiliogr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/bjd.19644","article-title":"Epidemiological changes in cutaneous lymphomas: An analysis of 8593 patients from the French Cutaneous Lymphoma Registry","volume":"184","author":"Dobos","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2004-04-1594","article-title":"Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling","volume":"105","author":"Hoefnagel","year":"2005","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/his.13832","article-title":"Primary cutaneous large B-cell lymphomas: Relevance of the 2017 World Health Organization classification: Clinicopathological and molecular analyses of 64 cases","volume":"74","author":"Menguy","year":"2019","journal-title":"Histopathology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/0284186X.2021.1956689","article-title":"Primary cutaneous indolent B-cell lymphomas\u2014A retrospective multicenter analysis and a review of literature","volume":"60","author":"Sobas","year":"2021","journal-title":"Acta Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00066-019-01541-7","article-title":"De-escalated radiotherapy for indolent primary cutaneous B-cell lymphoma","volume":"196","author":"Oertel","year":"2020","journal-title":"Strahlenther. Onkol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3389\/fonc.2020.00651","article-title":"Primary Cutaneous B-Cell Lymphomas: An Update","volume":"10","author":"Vitiello","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hon.2919","article-title":"Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"39","author":"Kraft","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s40257-022-00704-0","article-title":"Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas","volume":"23","author":"Krenitsky","year":"2022","journal-title":"Am. J. Clin. Dermatol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/5\/1034\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:08:31Z","timestamp":1760105311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/5\/1034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,3]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["cancers16051034"],"URL":"https:\/\/doi.org\/10.3390\/cancers16051034","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,3]]}}}